You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
27 October 2026 - Clinical-stage biotechnology company Riboscience LLC announced on Monday the presentation of initial overall survival (OS) and immune activation data from the Phase 1a/b clinical trial of RBS2418, its oral inhibitor of ENPP1, at the...
27 October 2026 - Oncology-focused biopharmaceutical company Citius Oncology Inc (Nasdaq:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Monday preliminary, unaudited LYMPHIR (denileukin diftitox-cxdl) uni...
27 October 2026 - US biopharmaceutical company Cumberland Pharmaceuticals Inc (Nasdaq: CPIX) announced on Monday that it plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its ifetroban product candidate as ...
26 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported updated Phase 2 results showing median overall survival of 28.2 months with investigational petosemtamab plus pembrolizumab in first-line treatment of recurrent o...
26 October 2026 - Chinese biopharmaceutical company Akeso Inc (HKEX:9926) announced on Sunday the presentation of results from the randomised, controlled, double-blind, multicentre, registrational Phase III HARMONi-GI1 trial (AK112-309).The study eva...
26 October 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (Kelun-Biotech) (HKG:6990) announced on Sunday the presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, of ...
26 October 2026 - China-based Zhejiang Wenda Pharmaceutical Technology Co Ltd announced on Sunday the publication of its phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC) at the...